ViRexx Founders Inducted Into The BioIndustry Hall Of Fame

Edmonton, Alberta - ViRexx Medical Corp., a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that its co-founders Dr. Lorne Tyrrell and Dr. Antoine Noujaim were inducted into the Alberta BioIndustry Hall of Fame as members of the initial class of inductees. Dr. Tyrrell received the honour at the 7th Annual BioAlberta AGM and Awards Gala held last week in Calgary, and Dr. Noujaim was honoured posthumously.

"Dr. Tyrrell's induction into the BioIndustry Hall of Fame underscores the fact that he is one of the most innovative and respected people in the field of virology," said Douglas Gilpin, Chairman of the Board of ViRexx Medical Corp. "As our Chief Executive and Chief Scientific Officer, Dr. Tyrrell's experience and knowledge in anti-viral drug development is invaluable as he guides the commercialization strategy for our Chimigen program for the treatment of chronic hepatitis B and hepatitis C."

Dr. Tyrrell's research at the University of Alberta led to the development of the anti-viral drug, lamivudine, currently a first line treatment for chronic hepatitis B (HBV) infection marketed by GlaxoSmithKline. His exceptional contributions to medical research have been recognized by his peers through awards such as the ASTech Award for Innovation and Science in Alberta, the Kaplin Award for Excellence in Research, the Prix Galien Canada Medal, the Principle Award for Innovation from the Manning Foundation and the Order of Canada. Dr. Tyrrell is the co-discoverer of ViRexx's proprietary Chimigen vaccine technology. ViRexx's lead Chimigen candidate, HepaVaxx B Vaccine, has recently completed a Phase I trial.

Dr. Noujaim's vision and long standing commitment to technology transfer from university laboratories to the private sector were critical to the development of Alberta's life science sector. Research from Dr. Noujaim's laboratory resulted in the formation of several successful biotechnology companies. One of the products from his endeavors with these companies, OvaRex MAb, is today in a pivotal clinical trial. Dr. Noujaim succumbed to pancreatic cancer earlier this year before realizing his dream of seeing this drug approved for the treatment of ovarian cancer.

SOURCE: ViRexx Medical Corp.